Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
The four types of dementia most people don’t know exist 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
A team of Japanese scientists has developed a method that utilizes glucose and fragmented antibodies in reducing an abnormal accumulation of protein in the brains of mice with Alzheimer’s disease.
According to Takanori Yokota, a neurology professor at the university who was part of the team, they hope accomplishment will lead to the development of a new therapy that is safer and more efficient than its conventional antibody-used counterpart.
The amyloid beta protein accumulation in the brain is believed to trigger Alzheimer’s.
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine (iCONM), encapsulated fragments of an antibody that can attach itself to the protein and remove it from the brain into a so-called nanomachine.
They also attached glucose molecules to the nanomachine's surface, making it simpler for the brain to receive the antibody.
The mice with abnormally high levels of amyloid beta due to the disease were given injections of the encapsulated antibody fragments by the researchers. The agent was administered weekly for 10 weeks.
In contrast to just injecting them there, the study found that employing a nanomachine can deliver 80 times more antibody fragments to the brain.
It was also established that this technique can be used to get rid of amyloid beta lumps, which prevented the protein from gathering.
Because a whole antibody is too large to be placed in many places, the researchers chose to employ antibody fragments instead.
The result was a positive effect that was unanticipated.
Historically, the blood-brain barrier, which determines what to take in from blood vessels to protect the brain, prevented the entire prescribed medication to eliminate the protein from reaching the brain.
Therapeutic antibodies for Alzheimer's disease are well known for having undesirable side effects, such as inflamed brain swelling.
As the fragmented antibody lacks the portion that causes inflammatory reactions, the team anticipates that this side effect may be avoided.
